Abstract:(1) Background: Ferroptosis is an apoptosis-independent cell death program implicated in many diseases including cancer. Emerging evidence suggests ferroptosis as a promising avenue for cancer therapy, but the paucity of mechanistic understanding of ferroptosis regulation and lack of biomarkers for sensitivity to ferroptosis inducers have significantly hampered the utility of ferroptosis-based therapy. (2) Methods: We performed integrated dataset analysis by correlating the sensitivity of small-molecule compounds (n = 481) against the transcriptomes of solid cancer cell lines (n = 659) to identify drug candidates with the potential to induce ferroptosis. Generalizable gene signatures of ferroptosis sensitivity and resistance are defined by interrogating drug effects of ferroptosis inducers (n = 7) with transcriptomic data of pan-solid cancer cells. (3) Results: We report, for the first time, the comprehensive identification of drug compounds that induce ferroptosis and the delineation of generalizable gene signatures of pro- and anti-ferroptosis in pan-cancer. We further reveal that small cell lung cancer (SCLC) and isocitrate dehydrogenase (IDH1/2)-mutant brain tumors show enrichment of pro-ferroptosis gene signature, suggesting a unique vulnerability of SCLC and IDH-mutant tumors to ferroptosis inducers. Finally, we demonstrate that targeting class I histone deacetylase (HDAC) significantly enhances ferroptotic cell death caused by Erastin, an ferroptosis inducer, in lung cancer cells, revealing a previously underappreciated role for HDAC in ferroptosis regulation. (4) Conclusions: Our work reveals novel drug compounds and gene networks that regulate ferroptosis in cancer, which sheds light on the mechanisms of ferroptosis and may facilitate biomarker-guided stratification for ferroptosis-based therapy.

Unleashing Ferroptosis for Cancer Therapy with Warfarin.

Targeting Ferroptosis in Breast Cancer

Insights Into Ferroptosis, a Novel Target for the Therapy of Cancer

Ferroptosis as a potential target for cancer therapy

Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer

Ferroptosis in cancer therapy: a novel approach to reversing drug resistance

Exploring Ferroptosis-Inducing Therapies for Cancer Treatment: Challenges and Opportunities

Regulation of VKORC1L1 is critical for p53-mediated tumor suppression through vitamin K metabolism

Pioneering the future of cancer therapy: Deciphering the p53-ferroptosis nexus for precision medicine

Ferroptosis in Ovarian Cancer: A Novel Therapeutic Strategy

The role of ferroptosis in prostate cancer: a novel therapeutic strategy

Ferroptosis in cancer and cancer immunotherapy

Ferroptosis and Its Interaction with Tumor Immune Microenvironment in Liver Cancer.

Ferroptosis in Cancer Treatment: Another Way to Rome

Ferroptosis is an effective strategy for cancer therapy

The mechanisms and therapeutic targets of ferroptosis in cancer

Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer

Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers

Ferroptosis open a new door for colorectal cancer treatment

Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer

Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatment